SAB Biotherapeutics Warrant
SABSW
24 hedge funds and large institutions have $4.04M invested in SAB Biotherapeutics Warrant in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
2% more capital invested
Capital invested by funds: $3.97M → $4.04M (+$72K)
0% more funds holding
Funds holding: 24 → 24 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$214K |
| 2 |
OCAM
Owl Creek Asset Management
New York
|
+$188K |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$108K |
| 4 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$56.6K |
| 5 |
KC
Kepos Capital
New York
|
+$34.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTCM
Fir Tree Capital Management
New York
|
-$171K |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$157K |
| 3 |
ICM
Ionic Capital Management
New York
|
-$131K |
| 4 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
-$115K |
| 5 |
GCL
Glazer Capital LLC
New York
|
-$109K |
SABSW Hedge Fund Activity: Q3 2021 in Review
24 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q3 2021, worth a combined $4.04M — up 1.8% from $3.97M a quarter earlier.
Fund positioning in SABSW was balanced in Q3 2021: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 4 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $214K. The largest seller was Fir Tree Capital Management, exiting entirely with an estimated $171K sold.
- 24 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $4.04M of SAB Biotherapeutics Warrant stock for Q3 2021, up 1.8% quarter-over-quarter.
- 4 funds opened new SAB Biotherapeutics Warrant positions in Q3 2021 and 4 closed out, a net change of 0 holders.
- The largest SAB Biotherapeutics Warrant buyer in Q3 2021 was Balyasny Asset Management, an estimated $214K added.
- The largest SAB Biotherapeutics Warrant seller in Q3 2021 was Fir Tree Capital Management, an estimated $171K sold.
Based on aggregated 13F filings for Q3 2021.